# Lunai Bioworks Inc.: financial statements, quarterly

LNAI · Nasdaq · CIK 1527728 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/lnai.md) · [Financials](/companies/lnai/financials.md) · [Filings](/companies/lnai/filings.md) · [Insiders](/companies/lnai/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lnai/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001731122-26-000749.md) | [0.0 d](/filings/0001731122-26-001339.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001731122-26-000749.md) | not reported |
| Research and development | $m | [0.6](/filings/0001731122-25-000254.md) | [0.6](/filings/0001731122-25-000258.md) | [1.1](/filings/0001731122-25-000250.md) | [0.4 d](/filings/0001731122-25-001316.md) | [0.4](/filings/0001731122-25-001544.md) | [0.2](/filings/0001731122-26-000253.md) | not reported | not reported | [0.0](/filings/0001731122-25-001544.md) | [0.0](/filings/0001731122-26-000253.md) | [0.0](/filings/0001731122-26-000749.md) | [(0.1) d](/filings/0001731122-26-001339.md) |
| Operating income | $m | [(8.9)](/filings/0001731122-25-000254.md) | [(4.3)](/filings/0001731122-25-000258.md) | [(51.4)](/filings/0001731122-25-000765.md) | [(17.1) d](/filings/0001731122-25-001316.md) | [(53.3)](/filings/0001731122-25-001544.md) | [(4.5)](/filings/0001731122-26-000253.md) | [(4.2)](/filings/0001731122-26-000749.md) | [(127) d](/filings/0001731122-26-001339.md) | [(3.3)](/filings/0001731122-25-001544.md) | [(1.8)](/filings/0001731122-26-000253.md) | [(1.5)](/filings/0001731122-26-000749.md) | [(2.1) d](/filings/0001731122-26-001339.md) |
| Interest expense | $m | [0.2](/filings/0001731122-25-000254.md) | [0.3](/filings/0001731122-25-000258.md) | [0.3](/filings/0001731122-24-000807.md) | [0.3 d](/filings/0001731122-25-001316.md) | [0.3](/filings/0001731122-25-001544.md) | [0.1](/filings/0001731122-26-000253.md) | [0.2](/filings/0001731122-26-000749.md) | [0.2 d](/filings/0001731122-26-001339.md) | [0.1](/filings/0001731122-25-001544.md) | [0.1](/filings/0001731122-26-000253.md) | [0.1](/filings/0001731122-26-000749.md) | [(0.1) d](/filings/0001731122-26-001339.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(9.2)](/filings/0001731122-25-000765.md) | [(4.5)](/filings/0001731122-25-000765.md) | [(59.0)](/filings/0001731122-25-000765.md) | [(15.7) d](/filings/0001731122-25-001316.md) | [(44.2)](/filings/0001731122-26-000749.md) | [(7.3)](/filings/0001731122-26-000749.md) | [0.2](/filings/0001731122-26-000749.md) | [(127) d](/filings/0001731122-26-001339.md) | [2.8](/filings/0001731122-26-000749.md) | [(1.8)](/filings/0001731122-26-000749.md) | [(2.6)](/filings/0001731122-26-000749.md) | [(2.0) d](/filings/0001731122-26-001339.md) |
| Diluted EPS | $ per share | [(0.14)](/filings/0001731122-25-000254.md) | [(0.07)](/filings/0001731122-25-000258.md) | [(0.54)](/filings/0001731122-25-000765.md) | not reported | [(2.76)](/filings/0001731122-25-001544.md) | [(0.45)](/filings/0001731122-26-000253.md) | [0.00](/filings/0001731122-26-000749.md) | not reported | [0.13](/filings/0001731122-25-001544.md) | [(0.08)](/filings/0001731122-26-000253.md) | [(0.10)](/filings/0001731122-26-000749.md) | not reported |
| Basic EPS | $ per share | [(0.14)](/filings/0001731122-25-000254.md) | [(0.07)](/filings/0001731122-25-000258.md) | [(0.54)](/filings/0001731122-25-000765.md) | not reported | [(2.76)](/filings/0001731122-25-001544.md) | [(0.45)](/filings/0001731122-26-000253.md) | [0.00](/filings/0001731122-26-000749.md) | not reported | [0.13](/filings/0001731122-25-001544.md) | [(0.08)](/filings/0001731122-26-000253.md) | [(0.10)](/filings/0001731122-26-000749.md) | not reported |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.5](/filings/0001731122-23-002120.md) | [0.2](/filings/0001731122-24-000248.md) | [0.3](/filings/0001731122-25-000250.md) | [0.2](/filings/0001731122-25-001316.md) | [0.2](/filings/0001731122-25-000254.md) | [0.3](/filings/0001731122-25-000258.md) | [0.9](/filings/0001731122-25-000765.md) | [0.1](/filings/0001731122-26-001339.md) | [0.6](/filings/0001731122-25-001544.md) | [0.5](/filings/0001731122-26-000253.md) | [3.2](/filings/0001731122-26-000749.md) | [1.7](/filings/0001731122-26-001339.md) |
| Current assets | $m | [1.9](/filings/0001731122-23-002120.md) | [2.4](/filings/0001731122-24-000248.md) | [1.2](/filings/0001731122-25-000250.md) | [2.0](/filings/0001731122-25-001316.md) | [1.9](/filings/0001731122-25-000254.md) | [1.7](/filings/0001731122-25-000258.md) | [3.7](/filings/0001731122-25-000765.md) | [1.0](/filings/0001731122-26-001339.md) | [0.8](/filings/0001731122-25-001544.md) | [0.5](/filings/0001731122-26-000253.md) | [3.7](/filings/0001731122-26-000749.md) | [2.0](/filings/0001731122-26-001339.md) |
| Total assets | $m | [57.6](/filings/0001731122-23-002120.md) | [58.0](/filings/0001731122-24-000248.md) | [178](/filings/0001731122-25-000250.md) | [163](/filings/0001731122-25-001316.md) | [122](/filings/0001731122-25-000254.md) | [111](/filings/0001731122-25-000258.md) | [118](/filings/0001731122-25-000765.md) | [8.2](/filings/0001731122-26-001339.md) | [7.0](/filings/0001731122-25-001544.md) | [6.7](/filings/0001731122-26-000253.md) | [9.9](/filings/0001731122-26-000749.md) | [9.9](/filings/0001731122-26-001339.md) |
| Current liabilities | $m | [10.1](/filings/0001731122-23-002120.md) | [13.8](/filings/0001731122-24-000248.md) | [20.9](/filings/0001731122-25-000250.md) | [30.3](/filings/0001731122-25-001316.md) | [23.0](/filings/0001731122-25-000254.md) | [28.6](/filings/0001731122-25-000258.md) | [28.8](/filings/0001731122-25-000765.md) | [29.2](/filings/0001731122-26-001339.md) | [19.7](/filings/0001731122-25-001544.md) | [20.0](/filings/0001731122-26-000253.md) | [19.3](/filings/0001731122-26-000749.md) | [18.9](/filings/0001731122-26-001339.md) |
| Total liabilities | $m | [10.8](/filings/0001731122-23-002120.md) | [14.4](/filings/0001731122-24-000248.md) | [43.7](/filings/0001731122-25-000250.md) | [31.2](/filings/0001731122-25-001316.md) | [23.7](/filings/0001731122-25-000254.md) | [29.3](/filings/0001731122-25-000258.md) | [29.3](/filings/0001731122-25-000765.md) | [29.6](/filings/0001731122-26-001339.md) | [20.0](/filings/0001731122-25-001544.md) | [20.2](/filings/0001731122-26-000253.md) | [19.4](/filings/0001731122-26-000749.md) | [19.0](/filings/0001731122-26-001339.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [46.7](/filings/0001731122-25-000254.md) | [43.6](/filings/0001731122-25-000250.md) | [134](/filings/0001731122-25-000250.md) | [132](/filings/0001731122-26-001339.md) | [98.1](/filings/0001731122-26-000749.md) | [82.1](/filings/0001731122-26-000749.md) | [88.4](/filings/0001731122-26-000749.md) | [(21.3)](/filings/0001731122-26-001339.md) | [(13.0)](/filings/0001731122-26-000749.md) | [(13.5)](/filings/0001731122-26-000749.md) | [(9.6)](/filings/0001731122-26-000749.md) | [(9.0)](/filings/0001731122-26-001339.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,777)](/filings/0001731122-25-000254.md) | [(3,147) d](/filings/0001731122-25-000258.md) | [(2,634) d](/filings/0001731122-25-000765.md) | [(2,414) d](/filings/0001731122-25-001316.md) | [(2,016)](/filings/0001731122-25-001544.md) | [(2,560) d](/filings/0001731122-26-000253.md) | [(1,487) d](/filings/0001731122-26-000749.md) | [(1,811) d](/filings/0001731122-26-001339.md) | [(1,349)](/filings/0001731122-25-001544.md) | [(1,071) d](/filings/0001731122-26-000253.md) | [(1,027) d](/filings/0001731122-26-000749.md) | [(1,841) d](/filings/0001731122-26-001339.md) |
| Capital expenditure | $k | not reported | not reported | [5.3 d](/filings/0001731122-25-000250.md) | [23.6 d](/filings/0001731122-25-001316.md) | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001731122-26-000749.md) | [0.0 d](/filings/0001731122-26-001339.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [55.1](/filings/0001731122-23-002120.md) | [55.5](/filings/0001731122-24-000248.md) | [56.0](/filings/0001731122-25-000250.md) | [64.5](/filings/0001731122-25-000254.md) | [65.9](/filings/0001731122-25-000258.md) | [109](/filings/0001731122-25-000765.md) | [16.0](/filings/0001731122-25-001544.md) | [16.2](/filings/0001731122-26-000253.md) | [16.4](/filings/0001731122-26-000749.md) | [22.5](/filings/0001731122-25-001544.md) | [23.5](/filings/0001731122-26-000253.md) | [25.0](/filings/0001731122-26-000749.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,034,452 at 2026-10-13, from the cover of the [10-K filed 2026-10-13](/filings/0001731122-26-001339.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.